DELRAY BEACH, Fla., Oct. 16, 2026 /PRNewswire/ — According to MarketsandMarkets™, the CRISPR Market is projected to reach USD 6.12 billion by 2031 from USD 3.48 billion in 2026, at a CAGR of 12.0% during the forecast period.

Browse 388 market data Tables and 53 Figures spread through 319 Pages and in-depth TOC on “CRISPR Market – Global Forecast to 2031”

CRISPR Market Size & Forecast:

Market Size Available for Years: 2026–20312026 Market Size: USD 3.48 billion2031 Projected Market Size: USD 6.12 billionCAGR (2026–2031): 12.0%

CRISPR Market Trends & Insights:

North America accounted for the largest share, 49.7%, of the CRISPR market in 2025.By offering, products accounted for the largest share of 70.7% of the CRISPR market in 2025.By application, drug discovery & development accounted for the largest share of the CRISPR market in 2025.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134401204

The CRISPR market is expanding as pharmaceutical and biotechnology companies and academic & research institutes increasingly adopt gene-editing technologies to support drug discovery, functional genomics, therapeutic development, and agricultural research. CRISPR tools are widely used for gene knockout, knock-in, target identification and validation, disease modeling, cell line development, and high-throughput screening. Rising demand for precise, efficient genome editing is accelerating adoption of CRISPR kits & enzymes, libraries, gRNA solutions, and specialized screening and validation services. In addition, ongoing advances in CRISPR-Cas systems, gRNA design and optimization, base editing, prime editing, and gene delivery technologies are improving editing specificity, efficiency, and workflow scalability. The growing development of CRISPR-based therapies and wider application of gene editing across research and commercial settings are further supporting market expansion.

By offering, the products segment held the largest share of the CRISPR market in 2025.

By offering, the CRISPR market is segmented into products and services. In 2025, products accounted for the largest market share. This is mainly due to recurring demand for CRISPR kits, enzymes, libraries, guide RNAs, and other research consumables across gene-editing workflows. Pharmaceutical and biotechnology companies, as well as academic and research institutes, use these products for gene knockout, gene activation, functional genomics, target validation, and drug discovery. The growing adoption of CRISPR-based screening and increasing gene editing research further support product consumption. Continued development of advanced Cas enzymes, optimized guide RNA solutions, and ready-to-use CRISPR kits also supports the segment’s leading position.

By product type, the CRISPR kits & enzymes segment held the largest share of the CRISPR product market in 2025.

By product type, the CRISPR product market is segmented into CRISPR kits & enzymes, CRISPR libraries, and other products. In 2025, CRISPR kits & enzymes accounted for the largest market share. Their leading position is supported by their extensive use across routine gene editing, target validation, cell engineering, and functional genomics workflows. CRISPR kits provide researchers with standardized components for gene knockout, knock-in, and other genome editing experiments, while enzymes such as Cas9 and other Cas nucleases are core components of CRISPR workflows. Their broad applicability across pharmaceutical research, biotechnology R&D, and academic laboratories creates recurring demand. The availability of workflow-specific kits and improved CRISPR enzymes with enhanced editing performance further supports this segment’s dominance.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=134401204

By region, North America accounted for the largest share of the market in 2025.

In 2025, North America held the largest share of the CRISPR market. This is supported by strong biotechnology and pharmaceutical research activity, high investment in gene editing, and a well-established life sciences infrastructure. The US leads the region in CRISPR-based drug discovery, functional genomics, high-throughput screening, and therapeutic development. Leading CRISPR technology providers, biotechnology companies, academic research institutes, and pharmaceutical companies create strong demand for CRISPR products and services. Growing clinical development of gene-edited therapies and continued advancements in CRISPR-Cas systems, guide RNA technologies, and screening platforms further support market growth in North America.

Key Players

Leading players in the CRISPR companies include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Creative Biogene (US), Fujian SunyBiotech Co., Ltd. (China), EditCo (US), Caribou Biosciences, Inc. (US), and Lonza (Switzerland), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134401204

CRISPR Market – Investment & funding +Merger & Acquisition

Investment Funding Context

The CRISPR market is seeing increasing investment and funding activity, driven by expanding gene-editing therapeutic pipelines, advances in CRISPR-Cas technologies, and the growing development of next-generation approaches such as base editing, prime editing, and epigenetic editing. Investment activity is increasingly focused on improving editing precision and delivery, advancing therapeutic candidates through clinical development, and expanding applications across genetic diseases and other therapeutic areas. For instance, in January 2025, Tune Therapeutics raised USD 175 million in Series B financing to advance its epigenetic editing platform and therapeutic pipeline. The financing highlights continued investor interest in differentiated gene-editing technologies with potential to address a broader range of diseases. This funding activity supports technology development, clinical translation, and commercialization across the CRISPR market.

Revenue Shift Context

The CRISPR market is gradually shifting revenue from conventional CRISPR-Cas9 systems and basic gene-editing reagents toward higher-growth categories such as engineered Cas nucleases, advanced CRISPR kits, high-throughput screening solutions, base editing, prime editing, and specialized gene-editing services. The global CRISPR market is projected to increase from USD 3.48 billion in 2026 to USD 6.12 billion by 2031, at a CAGR of 12.0%, with a growing share of incremental revenues expected from advanced editing platforms, customized gRNA solutions, CRISPR libraries, cell line development, and screening & validation services. Meanwhile, conventional Cas9-based products remain an important revenue base, but next-generation editing technologies and specialized services are gaining adoption across pharmaceutical & biotechnology companies and academic & research institutes.

Mergers and Acquisitions

Mergers and acquisitions in the CRISPR market are being driven by the need to strengthen gene-editing technology portfolios, gain access to proprietary CRISPR platforms, expand therapeutic development capabilities, and acquire expertise in next-generation editing and delivery technologies. Such transactions also enable companies to broaden their presence across drug discovery, functional genomics, and CRISPR-based therapeutic development.

CRISPR MARKET: MERGERS AND ACQUISITIONS, JANUARY 2023–SEPTEMBER 2026

Company Revenue Share Details

The top four players collectively account for approximately 25-27% of the global CRISPR market, indicating a highly competitive landscape. This reflects established life sciences companies alongside specialized gene-editing technology and service providers. Key market participants include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Creative Biogene (US), Fujian SunvBiotech Co., Ltd. (China), EditCo (US), Caribou Biosciences, Inc. (US), and Lonza (Switzerland). These companies compete across CRISPR kits & enzymes, libraries, gRNA solutions, cell line development, screening & validation, and other gene-editing services. Continued innovation in advanced CRISPR systems, editing optimization, high-throughput screening, and specialized services is further intensifying competition across the market.

Browse Adjacent Market: Biotechnology Market Research Reports &Consulting

See More Latest Medical Devices Reports:

Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (gRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-In), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) – Global Forecast to 2029

Genomics Market Product (Reagents, Kits, Instruments), Services (Genome Profiling, Bioinformatics), Technology (Sequencing, PCR, ISH, Flow Cytometry), Study Type (Epigenomics), Application (Drug Discovery, Diagnostics, Agri) – Global Forecast to 2030

About MarketsandMarkets™  

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/crispr-technology-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/crispr-technology.asp

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/crispr-market-worth-6-12-billion-by-2031—exclusive-report-by-marketsandmarkets-302911142.html

Novogradac to Host 2026 Fall Renewable Energy Tax Credits Conference, Nov. 5-6 in Washington, D.C.

SAN FRANCISCO, Oct. 16, 2026 /PRNewswire/ — Clean energy professionals will gather to receive actionable, technical insights into navigating the evolving renewable energy tax credit (RETC) market at the Novogradac 2026 Fall Renewable Energy Tax Credits Conference, Nov. 5-6 at the Fairmont Washington, D.C. Georgetown.

Set at a pivotal moment for the renewable energy market and immediately after the 2026 mid-term elections, this conference will bring together attorneys, developers, investors, lenders, tax insurance providers and advisors to examine the policy, structuring and financing issues shaping RETC investments. Attendees will engage with practical, technically focused content regarding deal execution, market developments and the challenges industry professionals are facing.

Sessions at the conference will discuss recent federal developments affecting clean energy tax incentives, technical tax considerations shaping deal execution, the clean energy development landscape and how it is evolving, what is driving investor interest in certain properties, tax equity structures and more. The full conference agenda can be found here.

“This year, the RETC sector has been shaped by major changes in federal policy and guidance. It’s important to stay up to date with the current state of the market,” said Tony Grappone, a partner in Novogradac’s North Andover, Massachusetts, office and chair of the conference. “This conference offers a targeted experience centered on technical content and represents an opportunity to connect with other professionals facing similar challenges.”

The Novogradac 2026 Fall Renewable Energy Tax Credits Conference is co-hosted by Bildmore, CAC, Crux, Foley and Lardner, Monarch Private Capital, Nixon Peabody and Raymond James. Conference sponsors include Alliant, Alston & Bird, Aon, Concentro, Crowell & Moring, DLA Piper, Euclid Transactional, Foley Hoag, Foss & Company, Howden, Key State, Latham & Watkins, Lux Speed Capital, National Trust Energy Capital, Reunion, Ryan, Sugar Creek Capital and Summit Ridge Energy. Kutak Rock and Prince Lobel will be exhibitors at the conference.

Novogradac will host a pre-conference workshop Wednesday, Nov. 4. The Project Finance Primer: Fundamentals & Monetization workshop will provide insights into financing clean energy developments by using tax credits as part of the capital stack. Topics of discussion will include the state of the market, what incentives are available, various tax equity structures and hot topics such as foreign entities of concern, prevailing wage and apprenticeship, domestic content and more. Separate registration fees apply for the pre-conference workshop.

About Novogradac
Novogradac, which has been in business for more than 35 years, has grown to more than 800 employees and partners with offices in more than 25 cities. Tax, audit and consulting specialty practice areas for Novogradac include affordable housing, community development, historic rehabilitation and renewable energy. For additional information on Novogradac’s personnel and areas of expertise, visit www.novoco.com or call (415) 356-8000.

View original content:https://www.prnewswire.com/news-releases/renewable-energy-tax-credit-professionals-to-explore-changing-energy-policy-landscape-at-novogradac-conference-302910360.html

SOURCE Novogradac & Company LLP

MedTrainer ranks #1 in G2’s Fall 2026 Momentum Grid and Implementation Index for Healthcare Credentialing Software, highlighting strong market momentum and client success.

LAS VEGAS, Oct. 16, 2026 /PRNewswire-PRWeb/ — MedTrainer, the leading healthcare workforce compliance and credentialing software, is ranked #1 by G2 in both the Momentum Grid and the Implementation Index for Healthcare Credentialing Software. Together, these rankings demonstrate that healthcare organizations are choosing MedTrainer and succeeding with the software.

“More organizations are trusting us with their credentialing. Hearing that they’re not waiting months to see the difference is what matters,” says Steve Gallion, MedTrainer CEO. “We’ve invested heavily in the credentialing platform itself, and the experience around it. Momentum ranking tells us the market noticed. Implementation top score tells us our clients felt it.”

In the Fall 2026 G2 Reports, MedTrainer also earned Best ROI for Healthcare Credentialing Software and is a Momentum Leader in three categories, including Healthcare Compliance Software. Best Usability, Easiest Admin, and Easiest to Use awards round out the reports.

G2 is the largest and most trusted software marketplace, fueled by authentic customer reviews. Quarterly, G2 evaluates this trusted data and ranks listed products to help professionals make smarter software decisions.

Momentum Built on Giving Time Back to Healthcare

G2’s Momentum Grid measures where a market is moving. The healthcare compliance and credentialing software market is demanding faster, more automated processes to counteract workforce shortages and rising administrative overhead. MedTrainer anticipated these market shifts and has focused product innovation on features and workflows that deliver time back to healthcare teams. The innovation turns 15 software clicks into one. It automates manual processes, such as data entry and form-filling. MedTrainer has momentum because it’s solving the industry’s biggest operational problem.

Here are time-saving features already built into MedTrainer credentialing software:

Automated license verification: DEA and state licenses are retrieved directly from licensing boards into each provider profile, logging the name, date, time, and source URL of every verification so you always have an audit-ready record.Automated exclusions monitoring: Automated OIG, SAM, DMF, and state exclusion checks flag issues before they become compliance problems and help you maintain NCQA compliance.Automated tracking and alerts: Expiring licenses, certifications, and compliance gaps are flagged automatically to keep you audit-ready without overtime effort.Integrations: Seamlessly sync employee data with a Dataspring integration, public API, and direct integrations with leading healthcare HRIS.Real-time reports and dashboards: Track credentialing status across providers, payers, and locations to spot gaps and upcoming deadlines early, with customizable dashboards and scheduled reports delivered daily, weekly, or monthly.

Consolidating multiple tools into a single source of truth also saves time throughout a healthcare organization and is a priority for leadership. In August 2026, MedTrainer and Surglogs announced a unique partnership offering single sign-on access between the platforms, providing a total compliance solution. For the first time, industry-leading curated healthcare compliance training, policy management, incident reporting, sterilization logs, equipment checks, and provider credentialing are available through a single login. This partnership unites two of healthcare technology’s most trusted names, combining what each does best to deliver a unified ecosystem that no competitor can replicate.

#1 in Implementation Because Clients Come First

G2’s Implementation Index is a ranking built from real customer responses on how long it took to go live, how easy the platform was to set up, and how many users actually adopted it. A high implementation score across a growing client base means it’s working not just for one client, but for all. Healthcare organizations need credentialing software implementation to be as efficient as possible because credentialing delays result in lost revenue every day a provider cannot schedule with patients or earn revenue.

Earning the top spot for Healthcare Credentialing Software reflects MedTrainer’s intentional investment in clients. The company’s first Chief Client Officer joined MedTrainer early this year to establish executive-level focus to support the increased focus on supporting clients. A new training team has revamped the entire implementation process to streamline onboarding. Product updates over the past year have greatly simplified the data migration and provider document upload processes.

MedTrainer is in a unique position among its competition. In addition to healthcare credentialing software, the company also offers fully-managed credentialing services. A team of 125+ specialists maintains credentialing for more than 10,000 providers annually. This team has a direct line to the product development team, so innovation is rapid and very focused on the challenges credentialing specialists are experiencing. It’s in the company’s best interest to speed up credentialing, privileging, and enrollment tasks.

Healthcare Credentialing Software

MedTrainer is a Leader in the Momentum Grid ReportMedTrainer is #1 in the Implementation IndexMedTrainer has Best ROI, Most Implementable, and Highest User Adoption

Healthcare Compliance Software

MedTrainer is a Leader in the Grid Report and Momentum Grid Report

Healthcare Risk Management Software

MedTrainer is a Leader in the Momentum Grid ReportMedTrainer is Best Usability, Easiest Admin, and Easiest to Use

What MedTrainer Users Love

Here are some recent G2 reviews:

“What I like best about MedTrainer is that it gives us one centralized place to manage provider credentialing, documents, licenses, expirations, and required verifications. It has made it much easier to stay organized while managing a large number of providers across multiple states. I especially appreciate the ability to track credentialing requirements and quickly see what is complete, what is expiring, and what still needs attention. The platform has helped streamline our credentialing workflow, reduce manual tracking, and keep important provider information easily accessible.”

Kristal B., Credentialing Lead

“The course catalog has an incredible amount of training for my employees. The best part, however, is the support we get from the MedTrainer team!”

David B.C., Senior Director of Compliance

“I appreciate the way that MedTrainer is consistently improving the platform. Our employees are able to navigate it easily and complete their required trainings quickly. I love that I can email customer service and get a response within 24 hours!”

Danyel H., Human Resources Director

See Why G2 Reviewers Love MedTrainer

More than 32,000 healthcare sites rely on MedTrainer to streamline compliance with a unified digital platform that optimizes workflows and accelerates education, credentialing, and documentation.

As a leader in healthcare technology, we’re constantly innovating to give customers the best experience and the most capabilities within one platform.

Ready to see why G2 users love MedTrainer? Request a demo.

Media Contact

Vince Koehler, Chief Marketing Officer, MedTrainer, 1 888-337-0288, vince.koehler@medtrainer.com, https://medtrainer.com/

MedTrainer Media Relations, MedTrainer, 1 888-337-0288, mediarelations@medtrainer.com, https://medtrainer.com/

View original content to download multimedia:https://www.prweb.com/releases/medtrainer-credentialing-software-tops-g2-rankings-for-growth-and-getting-it-right-302909080.html

SOURCE MedTrainer